-
公开(公告)号:EP0584229B1
公开(公告)日:2003-07-23
申请号:EP92912173.9
申请日:1992-05-06
IPC分类号: C12N15/12 , A61K38/00 , C12N15/62 , C12N15/13 , C12P21/02 , C12N5/10 , C07K14/00 , C12P21/08
CPC分类号: C07K14/70564 , A61K38/00 , C07K14/70596 , C07K16/28 , C07K16/2854 , C07K2317/34 , C07K2319/00
-
公开(公告)号:EP0697880A1
公开(公告)日:1996-02-28
申请号:EP94914062.0
申请日:1994-04-06
IPC分类号: C12P21 , A61K38 , A61K39 , A61P7 , A61P11 , A61P13 , A61P15 , A61P17 , A61P29 , A61P35 , A61P37 , A61P43 , C07K14 , C07K16
CPC分类号: C07K16/2821 , A61K38/00 , C07K14/705 , C07K14/70546 , C07K14/70564 , C07K16/2839 , C07K16/2854 , C07K16/2896
摘要: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.
-
公开(公告)号:EP0697880B1
公开(公告)日:2001-08-22
申请号:EP94914062.8
申请日:1994-04-06
IPC分类号: A61K38/02 , A61K39/395
CPC分类号: C07K16/2821 , A61K38/00 , C07K14/705 , C07K14/70546 , C07K14/70564 , C07K16/2839 , C07K16/2854 , C07K16/2896
摘要: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.
-
公开(公告)号:EP0584229A1
公开(公告)日:1994-03-02
申请号:EP92912173.0
申请日:1992-05-06
IPC分类号: G01N33 , A61K38 , A61K39 , A61K45 , A61P17 , A61P19 , A61P25 , A61P29 , A61P35 , A61P43 , C07H21 , C07K14 , C07K16 , C07K19 , C12N5 , C12N15 , C12P21 , C12Q1 , C12R1
CPC分类号: C07K14/70564 , A61K38/00 , C07K14/70596 , C07K16/28 , C07K16/2854 , C07K2317/34 , C07K2319/00
摘要: Ligands glycoprotéiques de sélectines. L'invention concerne également des procédés et des moyens de préparation ainsi que des acides nucléiques codant ces ligands. En outre, l'invention concerne un procédé de traitement d'un symptôme ou d'un état associé à une liaison excessive de leucocytes circulant sur des cellules endothéliales par administration à un patient nécessitant un tel traitement d'un ligand glycoprotéique d'une sélectine.
-
-
-